Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CRIS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.62% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.70M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta 3.67 | 52 Weeks Range 1.02 - 8.29 | Updated Date 06/29/2025 |
52 Weeks Range 1.02 - 8.29 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -426.77% |
Management Effectiveness
Return on Assets (TTM) -52.08% | Return on Equity (TTM) -2951.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5164705 | Price to Sales(TTM) 2.03 |
Enterprise Value 5164705 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 0.46 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 10462200 | Shares Floating 8381832 |
Shares Outstanding 10462200 | Shares Floating 8381832 | ||
Percent Insiders 8.64 | Percent Institutions 44.65 |
Analyst Ratings
Rating 3 | Target Price 16.33 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. Founded in 2000, Curis initially focused on genomics-based drug discovery and has evolved to concentrate on clinical-stage drug development programs.
Core Business Areas
- Drug Development: Curis focuses on the discovery and development of novel drug candidates, primarily in the field of oncology.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Licensing: Curis collaborates with other pharmaceutical and biotechnology companies to advance the development and commercialization of its products.
Leadership and Structure
Curis is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Emavusertib: Emavusertib is an investigational oral IRAK4 inhibitor being developed for the treatment of lymphoma, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Currently in Phase 1 clinical trial. Competitors include companies developing other IRAK4 inhibitors or targeting similar lymphoma pathways.
- Fimepinostat: Previously partnered, rights returned to Curis. Competitors are other epigenetic therapies.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and a complex regulatory environment. Advances in genomics and personalized medicine are driving innovation in cancer therapeutics.
Positioning
Curis is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. Its competitive advantage lies in its pipeline of novel drug candidates and its expertise in drug development.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars globally. Curis is positioned to capture a portion of this market through the successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Experienced management team
- Focus on targeted cancer therapies
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in personalized medicine
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRTX
- VRTX
- GILD
Competitive Landscape
Curis faces competition from larger pharmaceutical companies with greater resources and established pipelines. Its success depends on its ability to develop and commercialize differentiated products.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial progress and ability to secure partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking partnerships, and exploring new therapeutic targets.
Summary
Curis Inc. is a clinical-stage biotechnology company with a focus on developing cancer therapeutics. They rely on clinical trial outcomes and partnerships for financial stability. While they show promise, their current financial state and reliance on drug development successes make them a risky investment. Curis needs to show positive clinical data and secure partnerships to improve its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available data and may not be exhaustive. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.curis.com |
Full time employees 34 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.